Cellromax Science셀로맥스사이언스

Cellromax Science's trailing profits remain positive but have fallen sharply from 2024 peak levels, and the share price is well below its 52-week high.

Cellromax Science, a Seoul-listed maker of health functional foods, over-the-counter medicines and cosmetics, reported trailing twelve-month revenue of ₩19.6B and net income of ₩3.8B to H1 2026, with ₩3.4B in cash and no borrowings listed. Its 2025 revenue grew 2.6% but operating income fell from ₩5.5B in 2024 to ₩2.8B, and the share price is down 20.4% over one year.

What stands out

• Trailing operating margin is 11% against 25.4% in 2024, so profitability has compressed considerably.
• Trailing net income of ₩3.8B is above trailing operating income of ₩2.2B, which the data does not explain.
• Valuation shows a P/E of 12 and P/B of 1.0, with a 4.6% dividend yield; the internal DCF base value is ₩3,934 versus a close of ₩4,050.
• The filings list several dividend decisions and a buyback trust contract, plus a trust contract termination report on 23 October 2026, but the data does not give the details of these.
• Foreign ownership is 0.6% and was unchanged over 60 days, while 20-day flows show foreign net selling and retail net buying.

What to watch

• Upcoming results and filings, including the next quarterly report, since the data does not include a schedule.
• Whether operating margin stabilises after the drop from 2024 levels.
• Progress of the Hong Kong online channel and planned expansion into other Asian markets, which the profile mentions but the data does not quantify.